Day: July 28, 2020

TORONTO, July 28, 2020 (GLOBE NEWSWIRE) — Dividend 15 Split Corp. (“the Company”) announces that its semi-annual financial statements and management report of fund performance for the six months ended May 31, 2020 are now available at www.sedar.com and the Company’s website at www.dividend15.com.For further information, please contact Investor Relations at 416-304-4443, toll free at 1-877-4-Quadra (1-877-478-2372), or visit www.dividend15.com.

TORONTO, July 28, 2020 (GLOBE NEWSWIRE) — Financial 15 Split Corp. (“the Company”) announces that its semi-annual financial statements and management report of fund performance for the six months ended May 31, 2020 are now available at www.sedar.com and the Company’s website at www.financial15.com.For further information, please contact Investor Relations at 416-304-4443, toll free at 1-877-4-Quadra (1-877-478-2372), or visit www.financial15.com.

ORION CORPORATION STOCK EXCHANGE RELEASE INSIDE INFORMATION   28  JULY 2020 at 9.45 p.m. EEST                      Orion’s phase 3 REFALS trial evaluating the efficacy of oral levosimendan in treatment of ALS patients did not reach its pre-specified endpointsOrion has completed the clinical phase 3 REFALS trial evaluating the efficacy and safety of oral levosimendan in the treatment of ALS (amyotrophic lateral sclerosis).The primary endpoint of the trial was to show a statistically significant difference between levosimendan and placebo in slow vital capacity (SVC) in supine position at 12 weeks compared to the baseline. An important secondary endpoint was to show a statistically significant difference between levosimendan and placebo in patient functionality measured by ALSFRS-R Scale (Revised Amyotrophic Lateral Sclerosis Functional...

ORION OYJ    PÖRSSITIEDOTE  SISÄPIIRITIETO              28.7.2020        KLO 21.45         Suun kautta annosteltavan levosimendaanin tehoa ALS-potilaiden hoidossa arvioiva Orionin faasi 3 REFALS-tutkimus ei saavuttanut asetettuja tavoitteitaanOrion on saanut päätökseen kliinisen vaiheen 3 REFALS -tutkimuksen, jossa tutkittiin suun kautta annosteltavan levosimendaanin tehoa ja turvallisuutta ALS-taudin (amyotrofinen lateraaliskleroosi) hoidossa.Tutkimuksen päätavoitteena oli osoittaa tilastollisesti merkitsevä ero levosimendaanin ja lumelääkkeen vaikutuksessa makuuasennossa mitattavaan hitaaseen vitaalikapasiteettiin (SVC) 12 hoitoviikon kohdalla. Tärkeä toissijainen tavoite oli osoittaa tilastollisesti merkitsevä ero levosimendaanin ja lumelääkkeen välillä niiden vaikutuksessa potilaiden yleiseen toimintakykyyn ALSFRS-R-asteikolla (Revised...

FREDERICTON, New Brunswick, July 28, 2020 (GLOBE NEWSWIRE) — Trius Investments Inc. (TSXV: TRU.H) (“Trius” or the “Company”) is pleased to announce that it has completed a minority investment in Pasofino Gold Limited (TSXV: VEIN) (“Pasofino”) by acquiring a total of 300,000 Pasofino shares via open market purchases for a total investment of $90,000. Pasofino is Trius’ first investment in the mining sector.Pasofino is a mining issuer listed on the TSX Venture Exchange. Pasofino’s principal business is the acquisition, exploration and development of mineral properties, including its existing Roger gold and copper project located in Quebec, Canada. Pasofino has also entered into an agreement to acquire all of the shares of ARX Resources Limited (“ARX”) which, subject to certain conditions, could provide Pasofino with an indirect 49%...

TORONTO, July 28, 2020 (GLOBE NEWSWIRE) — Cluny Capital Corp. (the “Company”) (TSXV:CLN.H), a capital pool company pursuant to Policy 2.4 of the TSX Venture Exchange (the “TSXV”), announces the completion of two shares for debt transactions. Pursuant to the transactions, the Company issued an aggregate of ‎1,058,53‎‎5‎ common shares at a deemed price of $0.06 per share in satisfaction of ‎$63,512.19‎ of indebtedness currently owed to two arm’s length parties pursuant to the previously announced unsecured convertible debentures for an aggregate principal amount of $56,500. The Company determined to satisfy the indebtedness with common shares in order to preserve its cash for use on working capital and the identification and evaluation of a Qualifying Transaction. All shares issued in satisfaction of the indebtedness are subject to...

RESULTSFIRST HALF OF 2020Consolidated Revenue: €112.1mConsolidated Growth: + 7.7%Organic Growth on a like-for-like basis: + 6.0%Profitability (EBITDA margin): 13.1%ANALYSISAttachmentSwordGroup_Q2 Results 2020 FV_28072020

RÉSULTATS1ER SEMESTRE 2020Chiffre d’Affaires Consolidé : 112,1 M€Croissance Consolidée : + 7,7 %Croissance Organique à périmètre constant : + 6,0 %Rentabilité (marge d’EBITDA) : 13,1 %ANALYSESPièce jointeSwordGroup_Resultats Q2 2020 VF_28072020

New York, New York, July 28, 2020 (GLOBE NEWSWIRE) — Greencity Acquisition Corporation (Nasdaq: GRCYU) (the “Company”) announced today that it closed its initial public offering of 4,000,000 units. The offering was priced at $10.00 per unit.The Company’s units are listed on The Nasdaq Capital Market (“Nasdaq”) and commenced trading under the ticker symbol “GRCYU” on July 24, 2020. Each unit consists of one ordinary share of the Company and one warrant, each warrant entitling the holder thereof to purchase one-half of one ordinary share of the Company at a price of $11.50 per whole share. Once the securities comprising the units begin separate trading, the ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “GRCY” and “GRCYW,” respectively.The Company has granted the underwriters a 45-day option to purchase...

Banco Comercial Português, S.A. informs about consolidated earnings in the 1st half of 2020AttachmentsEarnings Millennium bcp 2Q20_vEarnings presentation 1H 2020